Our data provide a mechanistic hypothesis: by inhibiting DHCR24, we might simultaneously disrupt tumor-promoting cholesterol synthesis and reverse the immunosuppressive TME—evidenced by its correlation with exclusion and dysfunction signatures—thereby converting “cold” tumors into ones more susceptible to immunotherapy. The gene discussed is DHCR24; the disease is neoplasm.